Across TCGA pan-cancer cohorts, SLX4IP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLX4IP data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLX4IP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLX4IP expression acts as an unfavorable survival marker.
HNSC and UCEC are the cancer types where SLX4IP Mutation most reproducibly stratifies survival.